CClinicalTrials.gg
Not yet recruitingNCT07549282Updated Jul 30, 2026

Intranasal Dexmedetomidine and Perioperative Myocardial Injury

A Phase 4 interventional study of Intranasal Dexmedetomidine and Normal saline in Coronary Heart Disease, Myocardial Injury and Myocardial Infarction, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

PCI is the standard treatment for CAD, yet perioperative myocardial injury occurs frequently in nearly 40% of patients. Perioperative stress and sympathetic overactivation break myocardial oxygen balance and lead to cardiac damage, which further raises short-term cardiovascular events and long-term mortality risks. Dexmedetomidine exerts cardioprotective effects by inhibiting sympathetic excitation, though intravenous use carries risks of hypotension and bradycardia. Intranasal dexmedetomidine shows equivalent efficacy with fewer side effects and better patient compliance. Since no standard perioperative anesthesia regimen exists for elective PCI patients and the clinical benefits of dexmedetomidine remain unconfirmed, this pilot study is designed to test the feasibility and safety of intranasal dexmedetomidine spray before launching large formal RCTs.

02

Conditions studied

  • Coronary Heart Disease
  • Myocardial Injury
  • Myocardial Infarction
  • Dexmedetomidine
03

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged between 18 and 85 years old;
  • Subjects are fully informed of the risks, benefits and alternative treatment regimens of intranasal dexmedetomidine administration. Written informed consent is signed by the subject themselves or their legal representative prior to any study-related procedures;
  • Confirmed diagnosis of coronary artery disease with objective evidence of myocardial ischemia or silent myocardial ischemia, and indications for elective percutaneous coronary intervention (PCI);
  • American Society of Anesthesiologists (ASA) physical status classification II to III (patients with mild to severe systemic underlying diseases; ordinary physical activities are markedly limited, yet mild daily activities can be performed).

Exclusion criteria

Exclusion Criteria:

  • Subjects with hypersensitivity or contraindications to dexmedetomidine, including severe sinus bradycardia (resting heart rate \<50 beats per minute), sick sinus syndrome, and second-degree or higher atrioventricular block without pacemaker implantation;
  • Severe cardiac dysfunction (left ventricular ejection fraction \<40%), New York Heart Association (NYHA) class III-IV heart failure, cardiogenic shock, or hemodynamic instability;
  • Poorly controlled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg), or hypotension (systolic blood pressure \<90 mmHg);
  • Coexisting obstructive sleep apnea hypopnea syndrome (OSAHS);
  • Body mass index (BMI) >30 kg/m²;
  • Use of agents that may interfere with the study drug within 1 week before surgery, including α₂ adrenergic receptor agonists (e.g., clonidine), receptor antagonists, and tricyclic antidepressants;
  • Cognitive assessment cannot be completed due to language, visual or hearing impairment;
  • Hepatic or renal insufficiency (alanine aminotransferase, aspartate aminotransferase, or serum creatinine exceeding 3 times the upper limit of normal reference values);
  • Nasal anatomical abnormalities that preclude intranasal spray administration;
  • Pregnant or breastfeeding women;
  • Participation in other conflicting clinical trials.
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine Group

    The subjects received intranasal dexmedetomidine (100 μg, sprayed equally into both nostrils, two sprays per nostril) 15 minutes before surgery in the preoperative preparation area.

    Drug: Intranasal Dexmedetomidine

  • Placebo comparator
    Normal saline Group

    The subjects were given an equal volume of normal saline intranasally, which contained no active ingredient.

    Drug: Normal saline

Interventions

  • DrugIntranasal Dexmedetomidine

    The subjects received intranasal dexmedetomidine (100 μg, sprayed equally into both nostrils, two sprays per nostril) 15 minutes before surgery in the preoperative preparation area.

  • DrugNormal saline

    The subjects were given an equal volume of normal saline intranasally, which contained no active ingredient.

05

What researchers measure

Primary outcomes

  1. Incidence of perioperative myocardial injury

    Definition of myocardial injury: In patients with a normal baseline cTn concentration (≤99th percentile upper reference limit \[URL\]), postoperative cTn elevation exceeding the 99th percentile URL; In patients with an elevated baseline cTn concentration (\>99th percentile URL) that was stable or decreasing, a postoperative cTn increase of \>20% from baseline, with an absolute value exceeding the 99th percentile URL.

    Time frame: From the end of surgery to 48 hours after surgery

Secondary outcomes

  1. Incidence of major perioperative myocardial injury

    For patients with normal baseline cTn levels, a cTn elevation exceeding 5 times the 99th percentile upper reference limit (URL) within 48 hours after PCI .For patients with elevated baseline cTn levels, the post-procedural cTn value must increase by \>20% from baseline, and the absolute post-procedural cTn value must exceed 5 times the 99th percentile upper reference limit (URL).

    Time frame: From the end of surgery to 48 hours after surgery

  2. Composite outcome at 30 days after PCI

    Consisting of: (1) myocardial infarction; (2) new-onset stroke or transient ischemic attack (TIA); (3) all-cause death; and (4) any unplanned revascularization.

    Time frame: 30 days after surgery

  3. Blood pressure stability

    Quantified by the absolute real variability of perioperative generalized mean arterial pressure (ARV-MAP). Calculation procedures are as follows: ① For continuous arterial blood pressure waveform data, calculate the mean MAP for each non-overlapping 15-minute time window. ② Compute the absolute value of the difference between the mean MAP of every pair of adjacent time windows. ③ Sum all these absolute values, then divide the total sum by the total observation duration (operative time). A lower ARV-MAP value indicates smaller temporal fluctuations in MAP, meaning more stable blood pressure.

    Time frame: From the start of the procedure to the end of the procedure

  4. Perioperative myocardial oxygen consumption

    Rate-pressure product (RPP) = heart rate (beats per minute) × systolic blood pressure (mmHg). Blood pressure and heart rate are recorded every 15 minutes after patients enter the operating room, and the mean value of RPP is calculated.

    Time frame: From the start of the procedure to the end of the procedure

Other outcomes

  1. Incidence of unplanned hospital readmission within 30 days after surgery

    Unplanned hospital readmission

    Time frame: 30 days after surgery

  2. Change in perioperative anxiety scores

    Anxiety was also assessed using the Perioperative Anxiety Scale-7 (PAS-7) , which ranges from 0 to 28, with higher scores indicating greater anxiety.

    Time frame: Before intervention; after intervention but before surgery; 1 day after surgery

  3. Sleep quality scores on postoperative day 1

    Sleep quality was assessed using the Richards Campbell Sleep Questionnaire (RCSQ), RCSQ uses a visual analog scale ranging from 0 to 100 for each item, where 0 represents the worst possible sleep condition (or the most negative description) and 100 represents the best possible sleep condition (or the most positive description). Patients are asked to place a slider at the position that best describes their sleep status the previous night. The total RCSQ sleep score is calculated as the mean of the first five items (Items 6-10). The sixth item (Item 11) assesses noise level and is scored separately.

    Time frame: Baseline, 1 day after surgery

  4. Hospitalization costs

    Hospitalization costs

    Time frame: Through patients discharge, an average of 2 days after surgery

  5. Postoperative pain scores

    Pain was assessed using the Numerical Rating Scale (NRS), ranging from 0 to 10, with higher scores indicating more severe pain.

    Time frame: Immediately after surgery

  6. Quality of life scores at 30 days after surgery

    Quality of life was assessed using the EuroQol Five-Dimensional Questionnaire (EQ-5D) EuroQol Five-Dimensional Questionnaire (EQ-5D): The EQ-5D includes a visual analog scale (EQ-VAS) ranging from 0 to 100, where higher scores indicate better health status.

    Time frame: 30 days after surgery

  7. Quality of life scores at 30 days after surgery

    Quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Kansas City Cardiomyopathy Questionnaire (KCCQ): The KCCQ consists of 23 items that quantify the following domains: physical limitations, symptoms (including symptom frequency, severity, and change over time), self-efficacy, social function, and quality of life. The total score ranges from 0 to 100, with higher scores representing better quality of life.

    Time frame: 30 days after surgery

  8. Length of hospital stay

    Length of hospital stay

    Time frame: Through patients discharge, an average of 2 days after surgery

  9. Acute adverse reactions

    drug reaction

    Time frame: From intervention to 6 hours after surgery

  10. Intraoperative hypotension

    Systolic blood pressure \<90 mmHg or \>30% decrease from baseline

    Time frame: From intervention to end of surgery

  11. Incidence of intraoperative hypoxemia

    Oxygen saturation \<90% lasting at least 30 seconds

    Time frame: From intervention to end of surgery

  12. Incidence of severe bradycardia

    Heart rate \<40 beats/min

    Time frame: From intervention to 6 hours after surgery

  13. Dosage of vasoactive agents

    Including atropine, norepinephrine and nitroglycerin

    Time frame: From intervention to 6 hours after surgery

06

Study locations

1 site
  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
    Hangzhou, Zhejiang, China
07

Registry details

Key details

Study ID
NCT07549282
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Aug 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jul 30, 2026

Study contacts

Min Yan, Doctor
Contact
zryanmin@zju.edu.cn
15888210247

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion